FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

10/30/23 8:08:07 AM ET

$CHRS

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CHRS alert in real time by email

Biologic License Application (BLA): 761240
Company: COHERUS BIOSCIENCES INC

Products on BLA 761240

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
LOQTORZI	TORIPALIMAB-TPZI	240MG/6ML(40MG/ML)	INJECTABLE;INJECTION	Prescription	None	No	No

Approval Date(s) and History, Letters, Labels, Reviews for BLA 761240

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
10/27/2023	ORIG-1	Approval		N/A; Orphan		Label is not available on this site.

Get the next $CHRS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CHRS

Date	Price Target	Rating	Analyst
8/16/2024	$4.00 → $1.50	Buy → Neutral	UBS
11/17/2023	$11.00	Outperform	Robert W. Baird
11/8/2023		Buy → Hold	Maxim Group
7/24/2023	$12.00	Buy	Citigroup
5/1/2023	$24.00	Buy	Truist
3/28/2023	$11.00	Neutral → Buy	UBS
6/14/2022	$7.00	Neutral	UBS
3/7/2022	$15.00	Overweight → Neutral	JP Morgan

More analyst ratings

$CHRS
Financials

Live finance-specific insights

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Wednesday, November 6, 2024, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through
10/30/24 4:20:00 PM ET
$CHRS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Thursday, August 8, 2024, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through the f
8/1/24 9:00:00 AM ET
$CHRS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
– Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million term loan, with debt maturity of May 2029 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS), today reported financial results for the quarter ended March 31, 2024 and recent business highlights: RECENT BUSINESS HIGHLIGHTS UDENYCA® RESULTS and ONBODY™ LAUNCH UPDATE UDENYCA net product sales were $42.7 million in Q1 2024, an increase of 18% compared to $36.2 million
5/9/24 4:01:00 PM ET
$CHRS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$CHRS
Leadership Updates

Live Leadership Updates

Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting functions at multi-billion-dollar global companies. Her experience includes more than 17 years at Merck, where she held positions of increasing financial management responsibility. As Global Controller at Merck, Ms. Karachun managed a global team responsible for all accou
6/5/24 9:00:00 AM ET
$CHRS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
– Recognized biopharma commercialization and market access leader to support Coherus' strategic vision and multiple product launches – REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced the appointment to its Board of Directors of biopharma commercialization and market access expert Michael Ryan, Pharm. D. Dr. Ryan has four decades of experience working in academia and the biopharmaceutical industry bringing high-value therapeutics to patients. Dr. Ryan's distinguished career includes most recently serving as Senior Vice President and Head for U.S. and Worldwide Value, Access, Pricing and Health Ec
7/20/23 4:04:53 PM ET
$CHRS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Coherus BioSciences Appoints Dr. Jill O'Donnell-Tormey to its Board of Directors
- Dr. O'Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute's efforts to advance cancer immunotherapies - REDWOOD CITY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (("Coherus", NASDAQ:CHRS) today announced the appointment of cancer immunotherapy leader Jill O'Donnell-Tormey, Ph.D., to its Board of Directors. Dr. O'Donnell-Tormey will also serve on the Nominating and Corporate Governance Committee of the Board of Directors. Dr. O'Donnell-Tormey is the Chief Executive Officer and Director of Scientific Affairs of the Cancer Research Institute ("CRI"), a nonprofit organization dedicated exclusively to
5/11/22 6:00:00 PM ET
$CHRS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Wednesday, November 6, 2024, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through
10/30/24 4:20:00 PM ET
$CHRS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
– Net revenue of $65.0 million in Q2 2024 – – CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination with LOQTORZI – – Bryan McMichael Appointed as Chief Financial Officer – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS), today reported financial results for the quarter ended June 30, 2024 and recent business highlights: RECENT BUSINESS HIGHLIGHTS UDENYCA® RESULTS UDENYCA net product sales were $50.9 million in Q2 2024, an increase of 19% compared to $42.7 million in Q1 2024 and a 60% increase compared to $31.7 million in
8/8/24 4:05:00 PM ET
$CHRS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Thursday, August 8, 2024, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through the f
8/1/24 9:00:00 AM ET
$CHRS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

Products on BLA 761240

Approval Date(s) and History, Letters, Labels, Reviews for BLA 761240

Original Approvals or Tentative Approvals

Chat with this insight

Recent Analyst Ratings for $CHRS

$CHRS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chief Financial Officer Mcmichael Bryan J

SEC Form 4 filed by President & CEO Lanfear Dennis M

SEC Form 4 filed by Chief Commercial Officer Reider Paul

$CHRS Financials

Live finance-specific insights

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

$CHRS Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Coherus BioSciences Inc.

Amendment: SEC Form SC 13G/A filed by Coherus BioSciences Inc.

SEC Form SC 13G/A filed by Coherus BioSciences Inc. (Amendment)

$CHRS Market Insights

Live Market Insights

Baird Maintains Outperform on Coherus BioSciences, Lowers Price Target to $8

Coherus BioSciences To Divest Hong Kong King-Friend Industrial Co. Ltd. For Cash Consideration Of $40M

Coherus BioSciences To Divest YUSIMRY In $40M Upfront All Cash Transaction

$CHRS Leadership Updates

Live Leadership Updates

Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors

Coherus BioSciences Appoints Dr. Jill O'Donnell-Tormey to its Board of Directors

$CHRS SEC Filings

$CHRS Press Releases

Fastest customizable press release news feed in the world

$CHRS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

SEC Form 10-Q filed by Coherus BioSciences Inc.

Coherus BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Coherus BioSciences Inc. filed SEC Form 8-K: Regulation FD Disclosure

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Coherus BioSciences downgraded by UBS with a new price target

Robert W. Baird initiated coverage on Coherus BioSciences with a new price target

Coherus BioSciences downgraded by Maxim Group

$CHRS FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

Recent Analyst Ratings for
$CHRS

$CHRS
Insider Trading

$CHRS
Financials

$CHRS
Large Ownership Changes

$CHRS
Market Insights

$CHRS
Leadership Updates

$CHRS
SEC Filings

$CHRS
Press Releases

$CHRS
Analyst Ratings

$CHRS
FDA approvals